This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Kenta Haraya, Ph.D.
Group Manager Research Division, Discovery Biologics at Chugai Pharmaceutical Co., Ltd.


I’m a group manager of DMPK group in Discovery Biologics Department at Chugai Pharmaceutical. I joined in Chugai in 2008 and has been responsible for the pharmacokinetics of biologics project in discovery and preclinical development until now. From 2013 to 2017, I worked in Chugai Pharmabody Research in Singapore to promote several antibody projects utilizing antibody engineering technologies such as recycling antibody, sweeping antibody.

Agenda Sessions

  • Fc Engineering for Maximizing Soluble Target Antigen Sweeping Efficacy by Enhanced FcγRIIb Binding and Charge Modulation